Login
Related Links
Advertise on this site?
Advertising opportunities on Gene Therapy Net include standard size banners as well as text ads. Click here for more information about advertising.
You can also make a donation by PayPal and support the Gene Therapy Net website.
Companies - A
Addgene Non-profit organization working with hundreds of laboratories to assemble a high-quality library of published plasmids for use in research and discovery. By linking plasmids with articles, scientists can always find data related to the materials they request. |
|
Advanced Cell & Gene Therapy, LLC Consulting firm in cell therapy, gene therapy and tissue therapies, serving biotechnology companies, clinical laboratories, and biotechnology investors. |
|
Advanced Vision Therapies, Inc. Gene transfer technology for the treatment of eye diseases like Wet Age-Related Macular Degeneration (AMD), Diabetic Proliferative Retinopathy (DPR), Retinitis Pigmentosa (RP) and Dry Age-Related Macular Degeneration. |
|
AlphaVax Human Vaccines, Inc. AlphaVax is developing a new vaccine technology, alphavaccines, with broad applications against cancer and infectious disease, like pandemic influenza and cytomegalovirus. |
|
Altogen Biosystems Life sciences company dedicated to the development, marketing and manufacture of cell line specific transfection reagents for intracellular delivery of biomolecules (siRNA and plasmid DNA). |
|
American Gene Technologies Gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications. The company expects its lead candidate for an HIV cure to enter the clinic in 2018, and it has developed a patented immuno-oncology approach to attack a variety of epithelial cancers that is expected to enter trials soon. |
|
Applied Tissue Technologies LLC Technologies focus on direct methods of treating infection in skin wounds, transplanting skin to wounds, and delivering genes to skin cells. |
|
Ark Therapeutics Ltd. Gene therapy company focuses on areas of high unmet clinical need in vascular disease, wound care and cancer. Products in late stage clinical development: Cerepro®, Vitor™ and Trinam® |
|
Arthrogen An Amsterdam based clinical stage, biopharmaceutical company, is developing local gene therapy for inflammatory diseases, using viral mediated gene transfer. The first target indication is in the field of rheumatic diseases. Currently two phase Ib trials are ongoing, one in Canada and one in the Netherlands. |
|
Asklepios BioPharmaceutical Inc. Biotechnology company engaged in the development and delivery of novel protein and cellular based therapies through design of Biological Nano Particles (BNP). BNPs are synthetically designed from components of different Adeno Associated Viruses as well as other parvoviruses. |
|
Athersys, Inc. Clinical stage biopharmaceutical company with lead programs in the areas of obesity, cardiovascular disease (myocardial infarction), and bone marrow transplant support. |
|
Austrianova Focused on the development and manufacture of highly innovative tumour treatments based on localized cell therapies. Reference product NovaCaps® is the first encapsulated cell product targeting solid tumours. |
|
Companies - B
Batavia Biosciences B.V. Batavia Biosciences is a contract development and manufacturing organization, specialized in vaccines and gene therapies. |
|
Bavarian Nordic A/S Biopharmaceutical company developing and producing innovative vaccines by using vaccine (MVA) vectors for the development of vaccines against various infectious diseases such as smallpox, HIV/AIDS, as well as against breast and prostate cancer. |
|
BioCardia Inc BioCardia's Helix Biotherapeutic Delivery business remains committed to being the platform of choice for delivery of therapeutic agents to the myocardium. |
|
Bioheart, Inc. Biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Lead product candidate is MyoCell. |
|
Boster Bio Boster Bio specializes in the development and manufacturing of high-quality antibodies and ELISA kits, aiding scientific research in various fields such as cancer, neuroscience, and developmental biology. |
|
Companies - C
Cardium Therapeutics Medical technology company primarily focused on the development and commercialization of novel biologic therapeutics and medical devices for cardiovascular and ischemic disease. |
|
CD Bioparticles CD Bioparticles specializes in the development of tools for gene delivery and therapy, offering scientists various customized solutions, including DiagPoly™ PEI PLGA Nanoparticles and DNA & RNA Delivery Particles. The company also provides custom nucleic acid delivery particle synthesis and construction services applicable to gene therapy research. . |
|
Cellectis SA Cellectis proprietary technologies and platform are based upon a naturally occurring class of DNA endonucleases, the Meganucleases and DNA recombination. |
|
Cellerant Therapeutics Inc. Biotechnology company with a portfolio of products based on the regulation of the hematopoietic (blood-forming) system. Cellerant is developing a novel, cell-based medicine (Myeloid Progenitors / CLT-008) as a treatment for chemotherapy- and radiation-induced neutropenia as well as for Acute Radiation Syndrome. |
|
CellGenix Technologie Transfer GmbH CellGenix develops, manufactures and markets cell and protein therapeutics for cancer and orthopedic patients, as well as high-quality reagents for therapeutic ex vivo cell processing. |
|
Cenix BioScience GmbH Cenix is a contract research provider specialized in RNAi- and miRNA-based Target Discovery, Target Validation and Drug Mode of Action studies combined with high-content phenotypic analyses. |
|
Clontech Biotechnology supply company offering adenoviral-mediated gene transfer products, like Adeno-X Tet-On®, Adeno-X Tet-Off® Expression Systems for inducible adenoviral protein expression, Adeno-X Virus Purification Kit, Adeno-X Rapid Titer Kit, and Adeno-X Marker Viruses. |
|
Cobra Biologics Ltd Contract manufacturing organisation focusing on the production of Protein, Viral and DNA-based therapeutics at cGMP grade. | |
Copernicus Therapeutics Inc. Biopharmaceutical company utilizing its breakthrough DNA nanoparticle technologies to produce safe and effective DNA drugs. Copernicus' lead products is for cystic fibrosis and hemophilia B. |
|
Creative Biolabs With years of experience in one-stop pre-clinical development services, Creative Biolabs has built a team of experts with solid knowledge regarding gene therapy who are fully competent in services including delivery vehicle development, potency tests, safety and toxicology analysis, solutions of specific gene therapy development for diseases, etc. |
|
Creative Diagnostics Creative Diagnostics offers a variety of research tools and materials related to gene therapy, including AAV antibodies, antigens, ELISA kits, and other reagents specifically designed for gene therapy, and is committed to helping researchers develop AAV-based gene therapy products for various diseases. |
|
Cytologics Provider of human immune cells supporting biopharma companies and research organizations in early-stage discovery of therapies, clinical trials, quality control, manufacturing and commercialization. Their products range from HLA-typed PBMCs to specialty blood products to support biomedical research |
|
Companies - E
Enzo Biochem, Inc. Biotechnology company focused on the development of enabling technologies in the areas of gene regulation and gene modification. |
|
Companies - F
Florida Biologix A CMO that provides process development solutions, customized manufacturing, aseptic filling and other cGMP services for Phase I/II mammalian cell derived products such as vaccines, gene therapeutics, and protein products. |
|
Companies - G
Gene Medicine Japan Inc. Japanese based company committed to research and develop innovative gene medicine technologies such as adenoviral vectors and cell processing. |
|
Genemedi Biotechnology company with long standing expertise in AAV production, AAV vector optimizion, capsid evolution and new AAV generation. |
|
GenePharma Shanghai The company has internationally lead siRNA chemical synthesis complete core technology, including RNA monomer synthesis technology, common and chemically modified siRNA oligo synthesis technology. |
|
Genlantis Commercial firm focused on developing reagents for transfection, gene expression, gene Silencing, RNA interference, primary cell culture, and sample preparation in proteomics research. |
|
Genomics, Inc. Shanghai Company's mission is to develop novel therapeutic products for diseases prevalent in Asia, especially in the areas of lung fibrosis, liver fibrosis, cancer, and new biomaterials for bone healing. Shanghai Genomics also provides drug registration services and operates as a clinical research organization (CRO). | |
George Clinical George Clinical is a leading clinical contract research organisation company in Asia with over 260 global staff. George Clinical provides the full range of clinical trial services to pharmaceutical, medical device and biotech customers, for all trial phases, registration and post-marketing trials. George Clinical combines scientific and clinical leadership with expert trial delivery capability to create a distinctive world-class service CRO. |
|
GenVec, Inc. Biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Lead product TNFerade™ is used in locally advanced pancreatic cancer, rectal cancer, melanoma, and head and neck cancer. GenVec uses adenovector technology to develop vaccines for infectious diseases. |
|
Companies - H
Henogen Belgium biomanufacturing company able to produce, purify and aseptically fill clinical batches of therapeutic proteins, monoclonal antibodies, plasmid DNA, vaccinal viruses or viral vectors for gene therapy. |
|
Companies - I
Ichor Medical Systems, Inc. Ichor is dedicated to the clinical application and commercialization of electroporation technology (TriGrid™ Delivery System) for the delivery of DNA drugs and vaccines to treat and prevent debilitating or life threatening diseases. |
|
Intercytex Limited Healthcare company using its proprietary cell therapy technology to develop innovative regenerative medicine products to restore skin and hair. |
|
InvivoGen Biotechnology company focused on providing innovative products to the scientific community worldwide. Primary objective is to take advantage of cutting-edge technologies to provide research tools that are high quality and easy to use. . |
|
Companies - K
Kyninno A preclinical contract research organization (CRO) providing customized services of in vitro and in vivo pharmacology, cell line engineering, therapeutic target identification, and antibody discovery powered by its unique proprietary assets of 3000+ engineered cell lines, bispecific and tri-specific antibody discovery mouse models, 5000-antibody specificity screening MPSA-AB5000 panel, and the KY-AITM antibody development artificial intelligence platform. |
|
Companies - L
Lentigen Corporation Biotechnology supply company focused on custom manufacture of lentiviral vectors by using LentiMax Production System. |
|
Lysogene Lysogene is a clinical stage pioneering biotechnology company in the field of gene therapy targeting severe genetic pathologies of the central nervous system in children. |
|
Companies - M
MaxCyte, Inc. Cell therapeutics company developing cell-based therapies. The company's proprietary, non-viral, ex vivo cell loading technology is used in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases. |
|
MediGene, Inc. MediGene concentrates on commercializing novel drugs in three therapeutic areas: cancer, autoimmune diseases, and skin diseases. |
|
Microbix Biopharmaceutical company specialized in developing biological technologies in the field of biotherapeutics, vaccines and non-therapeutic biologics, including Adeno-associated virus vectors (rAAV) and Adenoviral vectors. |
|
Mirus Corporation Biopharmaceutical company focused on developing innovative nucleic acid based technologies and products. Under development are RNAi gene silencing therapies based on Mirus’ proprietary Dynamic PolyConjugates™ delivery platform. |
|
Molecular Medicine, LLC Company is dedicated to providing a variety of development, manufacturing, and ancillary services for the viral vaccine and viral therapeutic marketplace. |
|
MolMed S.p.A Medical biotechnology company focused on discovery, R&D, and clinical validation of innovative therapies for the treatment of cancer. |
|
Mologen Holding AG Biotechnology company researching and developing innovative DNA-based drugs, inclding improving existing immunological drugs and therapies to combat cancer and developing state-of-the-art vaccines for the prevention and treatment of serious infectious diseases. |
|
Companies - N
Nature Technology Corporation Bioengineering technology company, providing industry solutions for design, research, process development and manufacturing of biologics, including gene-therapeutics and vaccines. |
|
Neurotech SA Biotechnology company dedicated to the development of sight-saving therapeutics for chronic retinal diseases. Neurotech’s lead product (NT-501) is in clinical development for the treatment of retinal degeneration and geographic atrophy. |
|
Companies - O
Omnia Biologics, Inc. Omnia Biologics provides customized manufacturing, cGMP services, and process development solutions for the development of vaccines, gene therapeutics, and biodefense products. |
|
Onyx Pharmaceuticals, Inc. Biotechnology company developing small molecule cancer treatments. Their lead product is Nexavar® (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets tumor cell proliferation and angiogenesis. |
|
ORCA Therapeutics B.V. Netherlands biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents (ORCA). |
|
OrphageniX OrphageniX is dedicated to treating Orphan Diseases utilizing Targeted Gene Alteration (TGA). The Company will focus its efforts on developing oligotherapy technologies. |
|
Oxford Genetics Ltd Oxford Genetics provides a wide range of genetic materials for the creation of plasmid and virus based gene expression systems. Using a modular DNA assembly system, creating complex genetic systems is made significantly more efficient. |
|
Oxford BioMedica Biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines for treatment for cancer (TroVax®), Parkinson’s disease and retinopathy. |
|
Companies - P
PlasmidFactory GmbH & Co. KG PlasmidFactory is the leading contract manufacturer of plasmid and minicircle DNA. The company offers the production of plasmids and minicircles in several quality grades: Research Grade and ccc Grade for research purposes and pre-clinical applications, High Quality (HQ) Grade as starting material for e.g. GMP production of RNA and viral vectors and GMP Grade for clinical applications. PlasmidFactory has its own separate, dedicated HQ production area with new laboratories to produce highly purified plasmid DNA. To avoid cross-contamination, only one plasmid per time is produced there. |
|
Polyplus-transfection Biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics. Our PEIpro product line is currently used for viral vectors (AAV, lentivirus) production for cell & gene therapy. We are the unique providers of a PEI suitable for use as raw material in GMP processes. |
|
Progenitor Cell Therapy, LLC. Contract Manufacturing company that is dedicated to bridging the gap between the concepts in the cell therapy industry and their therapeutic application in patient care by providing quality product service solutions. |
|
Puresyn, Inc. Develops separation and purification processes for manufacturing gene delivery products such as supercoiled plasmids, synthetic oligonucleotides, recombinant adenovirus and adeno-associated virus. |
|
Companies - R
Regulon Inc. Biotechnology company committed to the development of anti-cancer pharmaceuticals. Their objective in developing a broad range of low-toxicity drugs to be used in cancer therapy is based on liposomal encapsulation technology. |
|
Reneuron ReNeuron is a pioneer in stem cell research and development focused on cell therapy treatments designed to reverse the effects of major diseases such as stroke, diabetes and diseases of the retina. |
|
REPLICor Inc. Biopharmaceutical company developing entry inhibitors for the treatment of hepatitis C (HCV) and prevention of HCV re-infection following liver transplantation. The company also targets the hepatitis B and influenza markets. |
|
Companies - S
Sernova Corp. Cellular therapy company with platform technology for creating a local immunoprivileged site enabling the therapeutic transplantation of cells and cell-based gene therapy. |
|
SiBiono GeneTech Co., Ltd. Chinese biotechnology company commercialized the first gene therapy product Gendicine, a recombinant Human Ad-p53, used for cancer treatment. |
|
SIRION Biotech Specialized technology provider for viral vectors (LV, AV, AAV) and their application. The company offers several transduction enhancers applicable in gene therapeutic R&D, vector design, retargeting, novel serotypes and production. SIRION Biotech is a specialized technology provider catering to large Pharma companies and research Institutes working in Gene Therapy, Vaccination and Target Validation. |
|
StemCells Incorporated StemCells, Inc. is focused on the discovery and development of stem cell therapeutics to treat damage to or degeneration of major organ systems such as the Central Nervous System, Liver and Pancreas. |
|
Sunway Biotech Co., Ltd. This Shanghai based biotechnology company is the main developer of the H100 technology and genetically engineered adenoviruses for cancer treatments. It has successfully developed drugs to treat cancer such as H101, H102, and H103. |
|
Supratek Pharma Inc. Pharmaceutical company dedicated to the commercialization of anticancer therapeutics desperately needed by cancer patients with tumors that are resistant to available therapies. |
|
Companies - T
Transgene S.A. Biopharmaceutical company dedicated to the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseases. |
|
Companies - U
uniQure Company involved in the research and early development of human gene based therapies. uniQure has a product pipeline of several gene therapies in development: hemophilia B, acute intermittent porphyria, Parkinson’s disease and Sanfilippo. uniQure is the world leader for manufacturing of AAV-based products on a commercial scale. |
|
Companies - V
VBL Therapeutics VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biotechnology company focused on the discovery, development and commercialization of first in class treatments for cancer. VBL’s clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. To date, VBL has developed two programs based on these platforms – an oncology program and an anti-inflammatory program. VBL is based in Tel Aviv, Israel. |
|
Vector Gene Technology Company, Ltd. VGTC is a leader in recombinant adeno-associated virus (rAAV) large-scale manufacturing. Its novel AAV package and purification systems make the producing of AAV to be one of the most cost-effective AAV producing systems. |
|
Vical Incorporated Biotechnology company developing biopharmaceutical products based on DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases, like infections diseases and cancer. |
|
VirRx, Inc. Biotechnology company with a primary interest in cancer gene therapy. Its broad mission is to develop genetically modified "smart bomb" adenoviruses for use in treating human cancers. |
|
VIVEbioTECH S.L. A Spanish biotech company which specialises in gene transfer technologies, and in particular those related to the production of viral vectors under GMP conditions, and their gene therapy applications. |
|
Companies - W
Wyatt Technology Corporation Wyatt Technology is the recognized leader in light scattering instrumentation for characterizing the size, shape, composition and concentration of bionanoparticles (bioNP). Wyatt provides solutions for detailed bioNP characterization for R&D and regulatory filings; automated screening to develop formulations and production processes; and inline process analytics during bioNP production. |
|
Companies - Y
Yuhua Life Science & Technology Development Co., Ltd. Shanghai Yuhua devotes itself to the research, production and service of the biological high technology. The key object is to research and develop anticancer and cardiovascular pharmacon, and strive to develop original products with remarkable economic and social benefits. |
|
Information Companies
Overview of biotechnology companies involved in gene therapy and/or cell therapy, as well as contract research organizations (CRO) and medical supply companies.
The provided information about the companies is just a summary of the information giving on their websites and is therefore not always complete, correct and/or exhaustive. Please visit the companies websites for a complete picture of the company.
Your company not listed? Click here to submit.
Like to work for a company? Find here the perfect job in gene therapy.
Gene Therapy News
- AaviGen, SK pharmteco Announce Manufacturing Agreement for Heart Failure Gene Therapy - BioPharm International
Sat, 12 Oct 2024 17:37:1 GMT - HNSA-5487 Significantly Reduces IgG Levels, FDA Removes Hold on AOC 1001, DMD Gene Therapy Shows No Impact on Cardiac Outcomes - Neurology Live
Sat, 12 Oct 2024 13:09:1 GMT - Gene therapy benefits boys with rare brain disease, but hematologic cancer remains a risk - Healio
Fri, 11 Oct 2024 17:30:2 GMT - Fierce Pharma Asia—AstraZeneca-CSPC heart med deal; Astellas' gene therapy pact, new cell therapy site - FiercePharma
Fri, 11 Oct 2024 15:48:5 GMT - Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy - Benzinga
Fri, 11 Oct 2024 15:09:1 GMT - Buy, Sell, Hold: Cell and Gene Therapy - Pharmaceutical Technology Magazine
Fri, 11 Oct 2024 13:01:3 GMT - Magnetically regulated gene therapy tech offers precise brain-circuit control - Medical Xpress
Thu, 10 Oct 2024 20:25:0 GMT - Hubble Therapeutics Taps Andelyn to Manufacture Clinical Grade AAV for Eye Disorder Gene Therapy - Genetic Engineering & Biotechnology News
Thu, 10 Oct 2024 19:29:0 GMT - Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials - Yahoo Finance
Thu, 10 Oct 2024 19:22:1 GMT - Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials - Pharmaceutical Technology
Thu, 10 Oct 2024 18:24:3 GMT - Report gives update on boys with rare brain disease 6 years after gene therapy - UPI News
Thu, 10 Oct 2024 16:10:4 GMT - Sarepta’s gene therapy is fully approved, but its stock has tanked. Here’s why - STAT
Thu, 10 Oct 2024 16:02:5 GMT - Magnetically Regulated Gene Therapy Tech Offers Precise Brain-Circuit Control - Weill Cornell Medicine Newsroom
Thu, 10 Oct 2024 15:33:5 GMT - 7 Children Receiving Bluebird’s Gene Therapy Developed Blood Cancers: Study - BioSpace
Thu, 10 Oct 2024 15:18:5 GMT - Highly targeted approach supports ALS gene therapy development - ALS News Today
Thu, 10 Oct 2024 15:14:0 GMT